Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa
Condition(s):Retinitis Pigmentosa; Retinal Diseases; Retinal DegenerationLast Updated:June 9, 2021Completed
Hide Studies Not Open or Pending
Condition(s):Retinitis Pigmentosa; Retinal Diseases; Retinal DegenerationLast Updated:June 9, 2021Completed
Condition(s):Type II Gaucher DiseaseLast Updated:February 22, 2024Recruiting
Condition(s):Krabbe DiseaseLast Updated:March 15, 2024Not yet recruiting
Condition(s):Acute LHON; Onset Within Three Months; Onset Between 3 to 6 Months; Onset Between 6 to 12 Months; Onset Between 12 to 24 Months; Onset Between 24 to 60 Months; Onset Over 60 MonthsLast Updated:July 29, 2020Unknown status
Condition(s):Bietti’s Crystalline DystrophyLast Updated:June 5, 2023Recruiting
Condition(s):Leber Hereditary Optic NeuropathyLast Updated:September 17, 2020Active, not recruiting
Condition(s):Wet Age-related Macular Degeneration; Neovascular Age-related Macular DegenerationLast Updated:August 8, 2023Completed
Condition(s):To Evaluate the Scaling Clinical Study of AAV2-RPE65 Gene Therapy Agent (LX101) in Patients With Congenital Amaurosis (LCA)Last Updated:September 5, 2023Not yet recruiting
Condition(s):DysferlinopathyLast Updated:May 13, 2021Completed
Condition(s):Cystic Fibrosis LungLast Updated:January 8, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.